Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Public ClinicalTrials.gov record NCT01374906. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
Study identification
- NCT ID
- NCT01374906
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2011 (Actual)
- Primary completion
- Dec 21, 2016 (Actual)
- Completion
- Dec 21, 2016 (Actual)
- Last update posted
- May 22, 2018
2011 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ClinTriCo | Phoenix | Arizona | 85381 | — |
| University of California at Los Angeles UCLA Tiverton | Los Angeles | California | 90095 | — |
| Harbor-UCLA Medical Center LA Biomed | Torrance | California | 90509 | — |
| Emory University School of Medicine/Winship Cancer Institute G2304 - C2301 | Atlanta | Georgia | 30322 | — |
| Pituitary Center, Division of Endocrinology SC | Baltimore | Maryland | 21287 | — |
| University of Michigan Comprehensive Cancer Center SC-2 | Ann Arbor | Michigan | 48109-0944 | — |
| Mount Sinai School of Medicine Mt. Sinai Medical Center | New York | New York | 10029 | — |
| Oregon Health & Sciences University DeptofOregonHealth&Sciences(2) | Portland | Oregon | 97201 | — |
| University of Pennsylvania - Clinical Studies Unit Unniv SC | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Medical Center CSOM230G2304 | Nashville | Tennessee | 37212-3139 | — |
| Swedish Medical Center Swedish | Seattle | Washington | 98122-4379 | — |
| Medical College of Wisconsin MCW 2 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01374906, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01374906 live on ClinicalTrials.gov.